An evaluation of six placebo-controlled medical trials with one,134 total participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) had been affiliated with a bigger typical enhancement to the Ashworth scale for spasticity in multiple sclerosis individuals in comparison with placebo, although this did not attain statistical sig